Navigation Links
Cardium Presents First Quarter 2012 Financial Results and Recent Developments
Date:5/15/2012

trade shows.  During the first quarter, the Company exhibited Excellagen at the APWCA (American Professional Wound Care Association) 2012 Meeting and this month exhibited Excellagen at the SAWC Symposium on Advanced Wound Care Meeting in Atlanta, GA. 

Generx Commercial Development PlansDuring first quarter 2012, Cardium announced the initiation of the ASPIRE Phase 3 registration study to evaluate the therapeutic effects of its lead product candidate, Generx (Ad5FGF-4) in patients with myocardial ischemia due to coronary artery disease. The ASPIRE study, a 100-patient, randomized and controlled multi-center study to be conducted at up to six leading cardiology centers in the Russian Federation, is designed to further evaluate the safety and effectiveness of Cardium's Generx DNA-based angiogenic product candidate, which has already been tested in clinical studies involving 650 patients at more than one hundred medical centers in the U.S., Europe and elsewhere.  The efficacy of Generx will be quantitatively assessed using rest and stress SPECT myocardial imaging (Single-Photon Emission Computed Tomography) to sensitively measure improvements in microvascular cardiac perfusion following a one-time, non-surgical, catheter-based administration of Generx.  The Russian Health Authority has assigned Generx the therapeutic drug trade name of Cardionovo™ for marketing and sales in Russia.  Additional information about the Generx ASPIRE study is available at http://clinicaltrials.gov/ct2/show/NCT01550614?term=cardium&rank=1.Preclinical research conducted at Emory University provides further support for the apparent safety and effectiveness of Generx as a potential one-time non-surgical approach to the treatment of coronary heart disease. This important study demonstrated that induced transient ischemia, using a standard angioplasty balloon cath
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Cardium to Present at Upcoming Investor Conferences
2. Cardiums Exchange Listing Compliance Plan Accepted by NYSE Amex
3. Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans
4. Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments
5. Cardium to Present at the LifeTech Capital Miami Medical Investors Conference
6. Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product Portfolio
7. Cardium to Present at 10th Annual Biotech in Europe Investor Forum
8. Cardium Regains Listing Compliance With NYSE Amex
9. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
10. Cardiums Exchange Listing Compliance Plan Accepted by NYSE AMEX
11. Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Proove Biosciences , the commercial and research leader in ... test built upon research from their published P.A.I.N. Study. ... physicians with an objective way to understand theirs patient’s ... individuals. With this new test, physicians will be able ... that will affect their pain tolerance. , The P.A.I.N. ...
(Date:9/30/2014)... , September 30, 2014 ... browsing of chemistry in documents ... solutions and consulting services for life science research, ... and generate Markush structures from documents. ... intellectual property, however generating and understanding Markush structures ...
(Date:9/30/2014)... and ROCKVILLE, Md., Sept. 30, 2014 BioHealth ... on commercializing market-relevant biohealth innovations and increasing access to ... announced today that venture capitalist, Tania Fernandez , ... advisor. Dr. Fernandez will be a member of the ... will provide up to $50 million in seed and ...
(Date:9/30/2014)... September 30, 2014 The custom stainless ... Boston Product Show 2014. The Boston Area Chapter of ... 23rd annual, day-long event for Wed., Oct. 1 at ... to be the largest in ISPE Boston’s long history, ... of 3,000 attendees expected. , HOLLOWAY AMERICA President ...
Breaking Biology Technology:Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3
... Contract Research Organization Exceeds Expectations, MEMPHIS, ... Contract Research,Organization exclusively focused on oncology, announced ... exceeded projections as the company continues,to experience ... to,ACORN,s ability to consistently exceed client expectations, ...
... Pharma, Inc., a,diversified specialty pharmaceutical company, announced ... issues in the treatment of moderate to,severe ... dry eye medication Lacrisert(R),(hydroxypropyl cellulose ophthalmic insert), ... helps to retain,moisture, stabilize the tear film, ...
... -- 3SBio Inc. (Nasdaq:,SSRX), a leading biotechnology company ... primarily in China,today announced that it has filed ... for approval of NuLeusin for the treatment of ... is expected to,be the only treatment of this ...
Cached Biology Technology:ACORN CRO Continues Growth in Strong Third Quarter 2Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 2Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 3Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 4Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 53SBio Inc. Files for SFDA Approval of NuLeusin 23SBio Inc. Files for SFDA Approval of NuLeusin 33SBio Inc. Files for SFDA Approval of NuLeusin 4
(Date:9/30/2014)... you want your doctor to know what goes wrong with ... good idea to know what "normal" actually is. That,s where ... of the FASEB Journal comes in. ... transcriptomea key set of molecules that can help scientists "see" ... time. What,s more, they found never-before-detected gene activity and that ...
(Date:9/30/2014)... in German . ... to risky situations such as exposure to predators. Researchers ... in a long-term study on different populations of great ... and ambient temperature. High metabolic rates and low temperatures ... scenarios birds were more likely to approach potential predators. ...
(Date:9/30/2014)... perilous threats in today,s ocean. From overfishing and ... coral ecosystems are disappearing at unprecedented rates around ... corals surrounding the island of Moorea in French ... environment: coral guard-crabs. New research from the National ... Seabird McKeon and the museum,s predoctoral fellow Jenna ...
Breaking Biology News(10 mins):Scientists identify which genes are active in muscles of men and women 2Risky metabolism 2Smithsonian scientists discover coral's best defender against an army of sea stars 2
... Clinic researchers have designed a new tool for identifying ... Stephen Ekker, Ph.D., succeeded in switching individual genes off ... development. The study appears in the journal Nature ... on health-related problems such as how cancerous cells spread, ...
... The May issue of JAMIA, the top-ranked journal reporting ... scientific researchin print and onlineon healthcare,s hottest HIT-related topics, ... Editor-in chief Lucila Ocho-Machado bullets some of the rich ... "A secure protocol for protecting the identity ...
... NEW BRUNSWICK, N.J. From a bucket of seawater, scientists ... organisms as different as coral reefs and human disease. By ... demonstrated a possible way to address diverse questions such as ... it is about some Antarctic algae that allows them to ...
Cached Biology News:In a genetic research first, Mayo Clinic turns zebrafish genes off and on 2In a genetic research first, Mayo Clinic turns zebrafish genes off and on 3JAMIA reports on people, their information needs and social networks 2From a bucket of seawater, new understanding of the ocean 2From a bucket of seawater, new understanding of the ocean 3
Human RELT/TNFRSF19L MAb (Clone 238104)...
...
... assay kit measures NOS activity by monitoring ... This assay is simple, sensitive, and specific ... with both crude and purified enzyme preparations. ... for 50 total reactions. Radiolabeled arginine and ...
Human TSLP MAb (Clone 258136)...
Biology Products: